Thu, May 12, 2011
Wed, May 11, 2011
Tue, May 10, 2011
Mon, May 9, 2011
Sun, May 8, 2011
Sat, May 7, 2011
Fri, May 6, 2011
Thu, May 5, 2011
Wed, May 4, 2011
Tue, May 3, 2011
Mon, May 2, 2011
Fri, April 29, 2011
Thu, April 28, 2011
Wed, April 27, 2011
Tue, April 26, 2011
Mon, April 25, 2011
Fri, April 22, 2011
Thu, April 21, 2011
Wed, April 20, 2011
Tue, April 19, 2011
Mon, April 18, 2011
Sun, April 17, 2011
Fri, April 15, 2011

Exelixis Announces May 4th Webcast of Presentation at the Deutsche Bank Securities Health Care Conference


//health-fitness.news-articles.net/content/2011/ .. sche-bank-securities-health-care-conference.html
Published in Health and Fitness on Wednesday, April 27th 2011 at 13:21 GMT by Market Wire   Print publication without navigation


SOUTH SAN FRANCISCO, Calif.--([ BUSINESS WIRE ])--Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael Morrissey, Ph.D., the company's president and chief executive officer, will present at the upcoming Deutsche Bank Securities Health Care Conference at 12:55 p.m. EDT / 9:55 a.m. PDT on Wednesday, May 4, 2011 in Boston. During the presentation, Dr. Morrissey will review the most recent publicly available data for cabozantinib in castration-resistant prostate cancer (CRPC) and discuss the pivotal trial plans and regulatory strategy for the compound in CRPC. He will also discuss the companya™s 2011 financial outlook and provide a general business update.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors and Media at [ www.exelixis.com ].

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company's web site at [ www.exelixis.com ].


Publication Contributing Sources